CURIS INC Q4 FY2025 earnings call

• Take Aim lymphoma study in primary CNS lymphoma is making steady progress, with expected accelerated submissions in US and Europe after collaborative discussions with FDA and EMA, and ongoing enrollment. - M of Usertib studies are being expanded into additional NHL subtypes, with interest in exploring its potential in CLL; proof-of-concept study in CLL has begun activating sites in US and Europe and expects initial data at ASH annual meeting in December. - AML triplet study presented data at ASH meeting in December showing five of eight evaluable patients achieved MRD conversion when combining M of Acertib with azazitidine and venetoclax in AML patients who achieved complete remission on A's of N but remained MRD positive.

CURE supported net income of $19.4 million, or $1.23 per share, for the fourth quarter of 2025, compared to a net loss of $9.6 million, or $1.25 per share, in the same period of 2024. The 2025 full-year net loss was $7.6 million, or $0.58 per share, versus a $43.4 million net loss, or $6.88 per share, in 2024. Research and development expenses for the fourth quarter of 2025 were $5.8 million, down from $9 million in the same period of 2024. Full-year 2025 R\u0026D expenses were $28.3 million, versus $38.6 million in 2024. General and administrative expenses for the fourth quarter of 2025 were $2.9 million, down from $3.4 million in the same period of 2024. Full-year 2025 G\u0026A expenses were $14 million, versus $16.8 million in 2024. Cash and cash equivalents as of December 31, 2025, along with proceeds from financing, should enable planned operations into the second half of 2027.

• Advancing registrational study in PCNSL and initiating proof-of-concept study in CLL in 2026. - Cash position as of December 31, 2025, together with proceeds from financing, should enable planned operations into the second half of 2027.

• Forward-looking statements are subject to certain risks and uncertainties, and actual results may differ materially. - Uncertainties in clinical trial progress, such as enrollment challenges for rare diseases like PCNSL.

Q: How are you prioritizing trial progress between pivotal PCNSL versus CLL and AML?

A: Prioritizing NHL ahead of AML, with bulk of spend towards PCNSL currently, and CLL study just started; hope to have significant progress towards PCNSL registrational data set and initial CLL data by end of year.

Q: Updates on PCNSL enrollment?

A: Enrolling patients on track, though enrollment is choppy with patient recruitment varying month to month.

Q: Modeling for revenue in 2026 and beyond?

A: No meaningful revenue expected, as revenue stream from AeroVeg was small and already wound down.

Q: Expected update at ASH26 on CLL?

A: Expecting to have some data to talk through at ASH26, but details to be narrowed down closer to the conference; success in CLL study would involve deepening response towards complete remission and MRD negative.